Literature DB >> 21795470

The effects of NS5A inhibitors on NS5A phosphorylation, polyprotein processing and localization.

Dike Qiu1, Julie A Lemm1, Donald R O'Boyle1, Jin-Hua Sun1, Peter T Nower1, Van Nguyen2, Lawrence G Hamann2, Lawrence B Snyder2, Daniel H Deon2, Edward Ruediger2, Nicholas A Meanwell2, Makonen Belema2, Min Gao1, Robert A Fridell1.   

Abstract

Hepatitis C virus (HCV) non-structural protein 5A (NS5A) is a multi-functional protein that is expressed in basally phosphorylated (p56) and in hyperphosphorylated (p58) forms. NS5A phosphorylation has been implicated in regulating multiple aspects of HCV replication. We recently reported the identification of a class of compounds that potently inhibit HCV RNA replication by targeting NS5A. Although the precise mechanism of inhibition of these compounds is not well understood, one activity that has been described is their ability to block expression of the hyperphosphorylated form of NS5A. Here, we report that an NS5A inhibitor impaired hyperphosphorylation without affecting basal phosphorylation at the C-terminal region of NS5A. This inhibitor activity did not require NS5A domains II and III and was distinct from that of a cellular kinase inhibitor that also blocked NS5A hyperphosphorylation, results that are consistent with an inhibitor-binding site within the N-terminal region of NS5A. In addition, we observed that an NS5A inhibitor promoted the accumulation of an HCV polyprotein intermediate, suggesting that inhibitor binding to NS5A may occur prior to the completion of polyprotein processing. Finally, we observed that NS5A p56 and p58 separated into different membrane fractions during discontinuous sucrose gradient centrifugation, consistent with these NS5A phosphoforms performing distinct replication functions. The p58 localization pattern was disrupted by an NS5A inhibitor. Collectively, our results suggest that NS5A inhibitors probably impact several aspects of HCV expression and regulation. These findings may help to explain the exceptional potency of this class of HCV replication complex inhibitors.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21795470     DOI: 10.1099/vir.0.034801-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  24 in total

1.  Identification of novel human kinases that suppress hepatitis C virus infection.

Authors:  A Lee; S Liu; T Wang
Journal:  J Viral Hepat       Date:  2013-11-10       Impact factor: 3.728

Review 2.  Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use.

Authors:  Sabrina Bagaglio; Caterina Uberti-Foppa; Giulia Morsica
Journal:  Drugs       Date:  2017-07       Impact factor: 9.546

3.  Correlation between NS5A dimerization and hepatitis C virus replication.

Authors:  Precious J Lim; Udayan Chatterji; Daniel Cordek; Suresh D Sharma; Jose A Garcia-Rivera; Craig E Cameron; Kai Lin; Paul Targett-Adams; Philippe A Gallay
Journal:  J Biol Chem       Date:  2012-07-16       Impact factor: 5.157

4.  In Vitro Antiviral Profile of Ruzasvir, a Potent and Pangenotype Inhibitor of Hepatitis C Virus NS5A.

Authors:  Ernest Asante-Appiah; Rong Liu; Stephanie Curry; Patricia McMonagle; Sony Agrawal; Donna Carr; Laura Rokosz; Frederick Lahser; Karin Bystol; Robert Chase; Stuart Black; Eric Ferrari; Paul Ingravallo; Ling Tong; Wensheng Yu; Joseph Kozlowski
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

5.  Intragenic complementation of hepatitis C virus NS5A RNA replication-defective alleles.

Authors:  Robert A Fridell; Lourdes Valera; Dike Qiu; Melissa J Kirk; Chunfu Wang; Min Gao
Journal:  J Virol       Date:  2012-12-12       Impact factor: 5.103

6.  Involvement of hepatitis C virus NS5A hyperphosphorylation mediated by casein kinase I-α in infectious virus production.

Authors:  Takahiro Masaki; Satoko Matsunaga; Hirotaka Takahashi; Kenji Nakashima; Yayoi Kimura; Masahiko Ito; Mami Matsuda; Asako Murayama; Takanobu Kato; Hisashi Hirano; Yaeta Endo; Stanley M Lemon; Takaji Wakita; Tatsuya Sawasaki; Tetsuro Suzuki
Journal:  J Virol       Date:  2014-04-23       Impact factor: 5.103

7.  Characterization of a Threonine-Rich Cluster in Hepatitis C Virus Nonstructural Protein 5A and Its Contribution to Hyperphosphorylation.

Authors:  Christian Schenk; Max Meyrath; Uwe Warnken; Martina Schnölzer; Walter Mier; Christian Harak; Volker Lohmann
Journal:  J Virol       Date:  2018-11-27       Impact factor: 5.103

8.  The Disordered Region of the HCV Protein NS5A: Conformational Dynamics, SH3 Binding, and Phosphorylation.

Authors:  Zsófia Sólyom; Peixiang Ma; Melanie Schwarten; Michaël Bosco; Ange Polidori; Grégory Durand; Dieter Willbold; Bernhard Brutscher
Journal:  Biophys J       Date:  2015-10-06       Impact factor: 4.033

9.  NS5A inhibitors impair NS5A-phosphatidylinositol 4-kinase IIIα complex formation and cause a decrease of phosphatidylinositol 4-phosphate and cholesterol levels in hepatitis C virus-associated membranes.

Authors:  V Reghellin; L Donnici; S Fenu; V Berno; V Calabrese; M Pagani; S Abrignani; F Peri; R De Francesco; P Neddermann
Journal:  Antimicrob Agents Chemother       Date:  2014-09-15       Impact factor: 5.191

10.  Continuous de novo generation of spatially segregated hepatitis C virus replication organelles revealed by pulse-chase imaging.

Authors:  Hongliang Wang; Andrew W Tai
Journal:  J Hepatol       Date:  2016-09-04       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.